Drugs / Ursochol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03004118 Comparator | Jan 2017 → Nov 2025 overdue | dyspepsia | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ursochol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03004118 ↗ |
| Known as | ursodeoxycholic acid | “Cross-over, controlled, randomized, double blinded, placebo-controlled trial with a 4 week intake of ursodeoxycholic acid (ursochol) versus a 4 week intake of placebo” NCT03004118 ↗ |
| Route | Oral | “Oral intake.” NCT03004118 ↗ |